GLP-1 Receptor Agonists and Uses Thereof

Pfizer Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 62/435,533, filed Dec 16, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

Patent	Title	Holder	Status	Expires	Time remaining	Confidence
US 10,208,019	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. In force Term ends Dec 13, 2037 · High confidence	Pfizer Inc.	In force	Term ends Dec 13, 2037	Term ends Dec 13, 2037	High confidence
US 10,669,259	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. In force Term ends Dec 13, 2037 · High confidence	Pfizer Inc.	In force	Term ends Dec 13, 2037	Term ends Dec 13, 2037	High confidence
US 10,851,081	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. In force Term ends Dec 13, 2037 · High confidence	Pfizer Inc.	In force	Term ends Dec 13, 2037	Term ends Dec 13, 2037	High confidence
US 11,512,070	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. In force Term ends Dec 13, 2037 · High confidence	Pfizer Inc.	In force	Term ends Dec 13, 2037	Term ends Dec 13, 2037	High confidence
US 11,802,121	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. In force Term ends Dec 13, 2037 · High confidence	Pfizer Inc.	In force	Term ends Dec 13, 2037	Term ends Dec 13, 2037	High confidence
US 12,319,669	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. In force Term ends Dec 13, 2037 · High confidence	Pfizer Inc.	In force	Term ends Dec 13, 2037	Term ends Dec 13, 2037	High confidence
Application 19/196,906	GLP-1 Receptor Agonists and Uses Thereof Pfizer Inc. Pending Not granted	Pfizer Inc.	Pending	Not granted	not computed

7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.

6 of these are in force and held by Pfizer Inc..

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.